Top Markets
#1 Nesa Nesa +337.52%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +14.79%
#4 Status Status +14.51%
#5 Wrapped NXM Wrapped NXM +7.60%
#6 PondCoin PondCoin +7.41%
#7 Kinesis Silver Kinesis Silver +6.73%
#8 Venom Venom +6.55%
#9 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +6.48%
#10 Ontology Gas Ontology Gas +5.41%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Kedudukan dalam Saham #19725
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Harga Saham
$2.42
Disegerakkan terakhir: 2026-08-25
Modal Pasaran
$152.37M
Perubahan (1 hari)
5.22%
Perubahan (1 tahun)
39.88%
Negara
US
Perdagangan Connect Biopharma Holdings Limited (CNTB)

Kategori

Healthcare
Margin Operasi untuk Connect Biopharma Holdings Limited (CNTB)
Margin Operasi pada 2026 TTM: 0.00%
Menurut laporan kewangan dan harga saham terkini Connect Biopharma Holdings Limited, margin operasi semasa (TTM) ialah 0.00%. Pada akhir 2026, margin operasi syarikat ialah 0.00%.
Sejarah Margin Operasi untuk Connect Biopharma Holdings Limited dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
Tidak cukup data untuk tarikh yang disediakan.
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.